Metastatic CRC: Better tumor response and disease control with FTD/TPI vs regorafenib

Key clinical point: Patients with metastatic colorectal cancer (mCRC) who initiated trifluridine/tipiracil (FTD/TPI) had better tumor response and disease control than those who initiated regorafenib.

Major finding: Patients who initiated FTD/TPI vs regorafenib as index therapy had better real-world overall response rate (odds ratio [OR], 2.57; 95% confidence interval [CI], 1.38-4.80) and real-world disease control (OR, 2.52; 95% CI, 1.36-4.68). Overall, a similar proportion of patients treated with FTD/TPI and regorafenib discontinued treatment because of disease progression (P = .162), but discontinuation because of toxicity/intolerance was significantly lower with FTD/TPI than regorafenib (8.2% vs 24.2%; P < .001).

Study details: Findings are from a retrospective study of patients with mCRC who initiated FTD/TPI (n=126) or regorafenib (n=95) at a US tertiary oncology center.

,

Disclosures: This study was funded by Taiho Oncology Inc., Princeton, NJ, USA. No conflict of interests was disclosed.

Source: Patel AK et al. Oncologist. 2021 Aug 18. doi: 10.1002/onco.13942.